Sir Deryck and Lady Va Maughan Professor of Rheumatology, Department of Medicine, NYU Grossman School of Medicine / NYU Langone Health Director, Division of Rheumatology, NYU Grossman School of Medicine […]
Melissa and Paul Anderson President’s Distinguished Professor, Department of Neurology, Perelman School of Medicine, University of Pennsylvania Dr. Amit Bar-Or is the inaugural Melissa and Paul Anderson President’s Distinguished Professor […]
Developing a bioavailable DNAseIL3 biologic to degrade pathogenic autoantibodies and treat lupus and related autoimmune diseases.
Repurposing nuclear-penetrating autoantibodies from lupus and scleroderma patients as potent, safe inhibitors of pathogenic NETosis.
Building AI-powered digital avatars that simulate each patient's immune system to predict therapy response and accelerate precision immunotherapy development.
Advancing engineered CAR and CAAR T cell therapies across multiple autoimmune diseases through clinical trials, preclinical development, and industry partnerships.
A Yale News feature on Yale Ventures' five accelerator funds highlights the Colton Center for Autoimmunity's growing role in translating autoimmune research into startups, licenses, and real-world therapies.
A Colton-supported Yale study has produced ImmunoStruct, a machine learning model that improves personalized cancer vaccine design by incorporating the 3D structure of immune-activating peptides — now licensed to a Yale spinout.
Global leaders in autoimmune research gathered for the 2025 Colton Consortium Symposium last month, sharing breakthroughs from foundational science to translational therapies and forging collaborations to improve patient lives worldwide.
The Penn Colton Center has launched two new Centers of Excellence — HIT-AI, focused on AI-driven drug repurposing, and CREATE, pioneering mRNA therapies — to accelerate next-generation autoimmune diagnostics and treatments.
